Tuberous Sclerosis Complex Clinical Trial
Official title:
Randomized, Placebo-controlled, Double-blind and Double-dummy Clinical Trial Comparing the Safety, Tolerability, and Efficacy of Vigabatrin and Rapamycin in a Preventive Treatment of Infants With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the efficacy, tolerability, and safety of vigabatrin versus rapamycin as a preventive treatment in infants with Tuberous Sclerosis Complex (TSC).
This is a two-arm, randomized, double-blind and double-dummy, placebo controlled study to evaluate the efficacy, tolerability, and safety of vigabatrin versus rapamycin as a preventive treatment in infants with TSC. The study consists of 3 phases for each patient: screening, core blinded phase, and open-label follow-up phase. Patients who meet the eligibility criteria will be randomized to receive vigabatrin or rapamycin. The randomization ratio is 1:1. Randomization will be stratified by the sex and the presence of epileptiform activity on baseline videoEEG (video electroencephalography) recording (yes versus no). Approximately 60 infants are planned to be enrolled in the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT02687633 -
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
|
N/A | |
| Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
| Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
| Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
| Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
| Recruiting |
NCT01730209 -
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
| Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
| Recruiting |
NCT06392009 -
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
| Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
| Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
| Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
| Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
| Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
| Active, not recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
| Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 | |
| Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|